Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min


Autoři: Lisa L. Ross aff001;  A. Sarah Walker aff002;  Yu Lou aff003;  Allan R. Tenorio aff004;  Diana M. Gibb aff002;  Julia Double aff005;  Charles Gilks aff006;  Cynthia C. McCoig aff007;  Paula Munderi aff008;  Godfrey Musoro aff009;  Cissy M. Kityo aff010;  Heiner Grosskurth aff008;  James Hakim aff009;  Peter N. Mugyenyi aff010;  Amy Cutrell aff011;  Teodora Perger aff012;  Mark S. Shaefer aff001
Působiště autorů: Medical Affairs, ViiV Healthcare, Research Triangle Park, NC, United States of America aff001;  Medical Research Council Clinical Trials Unit, University College, London, United Kingdom aff002;  Statistics, PAREXEL International, Durham, NC, United States of America aff003;  Physicians Group, ViiV Healthcare, Research Triangle Park, NC, United States of America aff004;  Safety and Medical Governance, GlaxoSmithKline, Stockley Park, United Kingdom aff005;  School of Population Health, University of Queensland, Brisbane, Australia aff006;  Physicians Group, ViiV Healthcare, Tres Cantos, Spain aff007;  HIV Care Research Programme, MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda aff008;  Department of Medicine, University of Zimbabwe, Harare, Zimbabwe aff009;  HIV Clinical Trials Unit, Joint Clinical Research Centre, Kampala, Uganda aff010;  Healthcare Statistics, ViiV Healthcare, Research Triangle Park, NC, United States of America aff011;  Safety and Pharmacovigilance, ViiV Healthcare, London, United Kingdom aff012
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225199

Souhrn

A retrospective analysis of the randomized controlled DART (Development of AntiRetroviral Therapy in Africa; ISRCTN13968779) trial in HIV-1-positive adults initiating antiretroviral therapy with co-formulated zidovudine/lamivudine plus either tenofovir, abacavir, or nevirapine was conducted to evaluate the safety of initiating standard lamivudine dosing in patients with impaired creatinine clearance (CLcr). Safety data collected through 96 weeks were analyzed after stratification by baseline CLcr (estimated using Cockcroft-Gault) of 30–49 mL/min (n = 168) versus ≥50 mL/min (n = 3,132) and treatment regimen. The Grade 3–4 adverse events (AEs) and serious AEs (for hematological, hepatic and gastrointestinal events), maximal toxicities for liver enzymes, serum creatinine and bilirubin and maximum treatment-emergent hematology toxicities were comparable for groups with baseline CLcr 30–49 versus CLcr≥50 mL/min. No new risks or trends were identified from this dataset. Substantial and similar increases in the mean creatinine clearance (>25 mL/min) were observed from baseline though Week 96 among participants who entered the trial with CLcr 30–49 mL/min, while no increase or smaller median changes in creatinine clearance (<7 mL/min) were observed for participants who entered the trial with CLcr ≥50 mL/min. Substantial increases (> 150 cells/ mm3) in mean CD4+ cells counts from baseline to Week 96 were also observed for participants who entered the trial with CLcr 30–49 mL/min and those with baseline CLcr ≥50 mL/min. Though these results are descriptive, they suggest that HIV-positive patients with CLcr of 30–49 mL/min would have similar AE risks in comparison to patients with CLcr ≥50 mL/min when initiating antiretroviral therapy delivering doses of 300 mg of lamivudine daily through 96 weeks of treatment. Overall improvements in CLcr were observed for patients with baseline CLcr 30–49 mL/min.

Klíčová slova:

Adverse events – Creatinine – Hematology – Renal system – Toxicity – Zimbabwe


Zdroje

1. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother. 1996;40: 1514–1519. doi: 10.1128/AAC.40.6.1514 8726029

2. DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200 cells/microl. AIDS. 2008;22: 237–247. doi: 10.1097/QAD.0b013e3282f2d760 18097226

3. Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, et al; DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375: 123–131. doi: 10.1016/S0140-6736(09)62067-5 20004464

4. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification and stratification [Erratum in Ann Intern Med. 2003;139: 605]. Ann Intern Med. 2003;139: 137–147. doi: 10.7326/0003-4819-139-2-200307150-00013 12859163

5. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16: 31–41. doi: 10.1159/000180580 1244564

6. Elion R, Cohen C, deJesus E, Redfield R, Gathe J, Hsu R, et al; COL40263 Study Team. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study. HIV Clin Trials 2006;7: 324–333. doi: 10.1310/hct0706-324 17208898

7. Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips DH, et al; ARIES Study Team. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials 2010;11: 69–79. doi: 10.1310/hct1102-69 20542844

8. Reid A, Stöhr W, Walker AS, Williams IG, Kityo C, Hughes P, et al; Development of Antiretroviral Therapy Trial. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis. 2008;46: 1271–1281. doi: 10.1086/533468 18444867

9. Stöhr W, Reid A, Walker AS, Ssali F, Munderi P, Mambule I, et al; DART Trial Team. Glomerular dysfunction and associated risk factors over 4–5 years following antiretroviral therapy initiation in Africa. Antivir Ther. 2011;16: 1011–1020. doi: 10.3851/IMP1832 22024517

10. Wyatt CM, Klotman PE, D'Agati VD. HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Semin Nephrol. 2008;28: 513–522. doi: 10.1016/j.semnephrol.2008.08.005 19013322

11. Husain NE, Ahmed MH, Almobarak AO, Noor SK, Elmadhoun WM, Awadalla H, Woodward CL, Mital D. HIV-associated nephropathy in Africa: pathology, clinical presentation and strategy for prevention. J Clin Med Res. 2018;10: 1–8. doi: 10.14740/jocmr3235w 29238427

12. Fischetti B, Shah K, Taft DR, Berkowitz L, Bakshi A, Cha A. Real-world experience with higher-than-recommended doses of lamivudine in patients with varying degrees of renal impairment. Open Forum Infect Dis; 2018;5: ofy225. doi: 10.1093/ofid/ofy225 30302352

13. Michienzi SM, Schriever CA, Badowski ME. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. Int J STD AIDS. 2019;30: 181–187. doi: 10.1177/0956462418800865 30381029


Článek vyšel v časopise

PLOS One


2019 Číslo 11